Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30950617 | 0.81 | NPSR1 (0.80) | KMT2ANPSR1LMNAMEN1RECQL | |
| SCHEMBL30950630 | 0.81 | NPSR1 (0.78) | KMT2ANPSR1LMNAMEN1RECQL | |
| SCHEMBL24445728 | 0.80 | NPSR1 (0.77) | KMT2ANPSR1LMNAMEN1RECQL | |
| SCHEMBL29847323 | 0.80 | NPSR1 (0.77) | KMT2ANPSR1LMNAMEN1RECQL | |
| SCHEMBL30950633 | 0.78 | NPSR1 (0.74) | KMT2ANPSR1LMNAMEN1RECQL | |
| SCHEMBL30950634 | 0.76 | NPSR1 (0.70) | KMT2ANPSR1LMNAMEN1RECQL | |
| SCHEMBL1463891 | 0.75 | MMP1 (0.49) | KMT2ANPSR1LMNAMEN1ALDH1A1 | |
| SCHEMBL4306451 | 0.73 | ALDH1A1 (0.58) | KMT2ANPSR1LMNAMEN1ALDH1A1 | |
| SCHEMBL30950611 | 0.73 | NPSR1 (0.66) | KMT2ANPSR1LMNAMEN1RECQL | |
| SCHEMBL30950635 | 0.73 | NPSR1 (0.66) | KMT2ANPSR1LMNAMEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011014299-A2 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | CREBBP, TEAD1, SREBF1 | KMT2A 1636/4885NPSR1 3746/4885LMNA 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.